World-first psilocin binge eating disorder trial reveals improvement in all patients

by Swinburne University of Technology

edited by Swati Mestri, reviewed by Andrew Zinin

Swati Mestri

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

The GIST Add as preferred source

Swinburne University of Technology and Entropy Neurodynamics' world's first IV-infused psilocin binge-eating disorder trial has led to improvements in all participants.

Following completion of just two TRP-8803 treatments, 50% of patients did not experience a single binge-eating episode during the entire 84-day follow-up period.

This pilot trial resulted in a 73% reduction in binge-eating episodes for the six treatment-resistant participants, who also experienced a 50% reduction in anxiety, a 42% reduction in depression and a 61% improvement in quality of life.

Swinburne's director of clinical trials and project lead Susan Rossell is thrilled to have maintained the success of the trial at the four-week mark.

"Changing the lives of these six participants is a huge feat," she says.

"These were patients who had lived with binge-eating disorder for as long as 20 years and who had previously failed treatment. Before entering the study, patients averaged 2.3 binge-eating episodes every week.

"We hope that we can replicate these benefits across the millions of people suffering from this debilitating disorder around the world, and potentially even the millions of others experiencing other treatment-resistant mental illnesses who may have given up hope."

Entropy Neurodynamics Limited CEO Jason Carroll says these 12-week results are particularly encouraging.

"For us, durability is critical," he says.

"We are not seeking to develop another medicine that patients need to take every day. We are investigating whether a limited number of precision-controlled psychedelic treatments can produce a clinically meaningful benefit that persists long after dosing has finished.

"These are early data from a small study, but the regulatory direction and the clinical evidence we are generating are increasingly aligned. We believe these results provide increasing clinical validation of our precision-controlled approach and materially strengthen the clinical rationale for continued development of TRP-8803."

Swinburne and Entropy Neurodynamics are currently seeking participants for a second cohort to trial a shorter TRP-8803 infusion treatment regimen to further optimize treatment efficiency and clinical scalability.

Key medical concepts

Anxiety

Clinical categories

PsychiatryPsychology & Mental healthClinical pharmacologyWeight management Provided by Swinburne University of Technology Who's behind this story?

Swati Mestri

Swati Mestri holds a bachelor's degree in Electronics Engineering and has worked as a content editor since 2019. She has experience editing research documents across technology, health care, and materials science, and has a particular interest in technology and space. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: World-first psilocin binge eating disorder trial reveals improvement in all patients (2026, September 15) retrieved 15 September 2026 from https://medicalxpress.com/news/2026-09-world-psilocin-binge-disorder-trial.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.